MOdern Treatment of Inhibitor-PositiVe PATiEnts With Haemophilia A - An International Observational Study
Latest Information Update: 12 Sep 2024
At a glance
- Drugs Emicizumab (Primary) ; Eptacog alfa (Primary) ; Factor VIII inhibitor bypassing fraction (Primary) ; Factor VIII/von Willebrand factor (Primary) ; Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms MOTIVATE
Most Recent Events
- 10 Jun 2024 According to an Octapharma media release, data from the study will be presented at the upcoming ISTH 2024 Congress
- 06 Jun 2023 According to Octapharma media release, Coordinating investigators, Dr Carmen Escuriola Ettingshausen and Robert F.Sidonio Jr., will provide an update on this study status at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) on June 24-28, 2023, in Montreal, Canada.
- 28 May 2021 According to a media release, the study is supported by funding from Octapharma AG. Full logistical support from a contract research organisation (CRO) is available to all centers.